Fujian Cancer Hospital: Carcinoma trials
The registry lists 20 Carcinoma studies with Fujian Cancer Hospital as lead sponsor. 13 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 12Phase 3 3No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal CarcinomaNot yet recruitingNCT06572293Not applicable
- SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular CarcinomaNot yet recruitingNCT06538935Phase 2
- Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468670Phase 2
- Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06468644Phase 2
- A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06463834Phase 2
- Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
- Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of LifeNot yet recruitingNCT06136962
- Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPCNot yet recruitingNCT06095167Phase 3
- CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal CarcinomaRecruitingNCT06095154Phase 3
- XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell CarcinomaNot yet recruitingNCT05927844Phase 1
- Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and CisplatinRecruitingNCT05910177Phase 2
- A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker AnalysesNot yet recruitingNCT05897138Phase 2
- Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International GuidelinesNot yet recruitingNCT05519956Phase 3
- PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT05007145Phase 2
- Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Phase 2
- Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPCStatus unknownNCT04745741
- To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPCCompletedNCT04387266
- Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT04319471Phase 2
- Nimotuzumab for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT03666221Phase 2
- Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell CarcinomaStatus unknownNCT03486509Phase 2